Q&As About COVID-19 Therapeutics: Which to Use, When to Use, and with Whom? (Archive 2/17/22)

1.0 CME / 1.0 CMD Clinical

This webinar will review the current COVID-19 therapeutics available, examine benefits and risks of each medication, and discuss the accessibility to these therapies in the PALTC settings.

Learning Objectives

By the end of the webinar, participants should be able to:

  • Review the current COVID-19 therapeutics available on the market.
  • Review the benefits and risks of each medication and how to determine which is appropriate for your patient.
  • Discuss accessibility to these therapies in PALTC settings.

Speaker Information:

Moderator: Sabine von Preyss-Friedman, MD, FACP, CMD

Panel: Muhammad S. Ashraf, MD, MBBS; Amy Brotherton, PharmD, BCIDP, AAHIVP; Andrew B. Watkins, PharmD, BCIDP

Sabine von Preyss-Friedman, MD, CMD, FACP, is an associate clinical professor at the University of Washington and chief medical officer of Avalon Healthcare. She first became a Certified Medical Director in 1992 and has since been enthusiastically engaged in the practice of post-acute and long-term care. She is currently a member of AMDA’s Board of Directors and serves as president of AMDA's Washington State Chapter.

Muhammad S. Ashraf, MBBS, is an associate professor in the Division of Infectious Diseases, Department of Internal Medicine, at University of Nebraska Medical Center, Omaha, NE, where he also serves as the medical director for the Nebraska Infection Control Assessment and Promotion Program (ICAP) and co-medical director for the Nebraska Antimicrobial Stewardship Assessment and Promotion Program (ASAP). He is a member of SHEA Long-Term Care Special Interest Group, SHEA Education Committee, IDSA Antimicrobial Resistance Committee, and Infection Advisory Committee of AMDA – The Society for PALTC Medicine. Dr. Ashraf is currently working on multiple projects focused on promoting infection prevention and control and antimicrobial stewardship programs in long-term care facilities.

Amy Brotherton, PharmD, BCIDP, AAHIVP, is an assistant professor of medicine for Brown University Alpert Medical School and a clinical pharmacist specialist in Infectious Diseases at The Miriam Hospital Infectious Diseases and Immunology Center in Providence, RI. Dr. Brotherton works with a multidisciplinary team to provide comprehensive and compassionate care to patients living with HIV/AIDS. Additionally, she specializes in outpatient antimicrobial therapy (OPAT) and the treatment of opportunistic infections, hepatitis C, and multi-drug resistant HIV. Dr. Brotherton also serves on the Lifespan Antimicrobial Stewardship Program Committee and has played an integral role in the roll out of COVID-19 therapeutics in RI. She is a member of the Society of Infectious Diseases Pharmacists (SIDP) and the American College of Clinical Pharmacy (ACCP).

Andrew B. Watkins, PharmD, BCIDP, is an antimicrobial stewardship outreach pharmacist within the Nebraska Medicine Antimicrobial Stewardship Program as well as the pharmacy coordinator for Nebraska ASAP (Antimicrobial Stewardship Assessment and Promotion Program). Dr. Watkins received both his Bachelor of Science in Pharmaceutical Sciences and his Doctor of Pharmacy from the University of Mississippi. He completed residency training in pharmacy practice at St. Dominic Memorial Hospital in Jackson, MS and completed his infectious diseases specialty residency at Nebraska Medicine. His areas of interest include appropriate antimicrobial use and implementation of antimicrobial stewardship practices in acute care, long-term care, and outpatient settings. He is a member of the Society of Infectious Diseases Pharmacists (SIDP) and the American College of Clinical Pharmacy (ACCP). 


Credit Information:

Activity Created 2/2022

Credits Available Until 2/2025

Credit Statements: 

CME: AMDA – The Society for Post-Acute and Long-Term Care Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AMDA – The Society for Post-Acute and Long-Term Care Medicine for Post-Acute and Long-Term Care Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CMD: This self-study activity has been pre-approved by the American Board of Post-Acute and Long-Term Care Medicine (ABPLM) for a total of 1.0 clinical hours toward certification or recertification as a Certified Medical Director (CMD) in post-acute and long-term care medicine. The CMD program is administered by the ABPLM. Each physician should claim only those hours of credit actually spent on the activity.

Visit the Continuing Education page for information on if and how you can claim credit/hours for AMDA’s education.

Disclosure Information:

The Society requires the disclosure of all speaker/faculty/planner’s relevant financial relationships; presence of off-label use of a device or medication; and discussion of any experimental, new or evolving topic prior to each accredited education activity.

If the learner perceives any bias toward a commercial product or service, advocation of unscientific approaches to diagnosis or therapy, or recommendation, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients please report this to the Society’s staff.

All relevant financial relationships have been identified, mitigated, and resolved.

The following speaker(s) have financial relationships to report: Muhammad S. Ashraf, MD, MBBS – Merck & Co. Inc - Research Grant; all other speakers have no financial relationships to disclose.

The following AMDA Online Education Committee members have financial relationships to report: Robert Zorowitz, MD, MBA, CMD – United Health Group: Stock Shareholder; all others have no relationships to disclose.

AMDA staff have no relationships with ineligible companies.